



1642/1642  
JW

PTO/SB/21 (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/010,667	
	Filing Date	December 6, 2001	
	First Named Inventor	Daniel E. AFAR	
	Art Unit	1642	
	Examiner Name	G. B. Nickol	
Total Number of Pages in This Submission	9	Attorney Docket Number	511582001621

ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form, 1 pg in duplicate <input type="checkbox"/> Fee Attached  <input type="checkbox"/> Amendment/Reply  <input type="checkbox"/> After Final  <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input checked="" type="checkbox"/> Information Disclosure Statement, 3 pages  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Response to Missing Parts/Incomplete Application  <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s)  <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition  <input type="checkbox"/> Petition to Convert to a Provisional Application  <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Request for Refund  <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form 1449, 3 pages Return Postcard
<div>Remarks</div> <p><b>CUSTOMER NO. 25225</b></p>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	MORRISON & FOERSTER LLP Kate H. Murashige - 29,959
Signature	<i>Kate H. Murashige</i>
Date	June 15, 2004

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.	
Dated: 6-15-04	Signature: <i>Rhea Amid</i> (Rhea Amid)



# FEE TRANSMITTAL for FY 2004

Effective 10/01/2003, Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 180.00

## Complete if Known

Application Number	10/010,667
Filing Date	December 6, 2001
First Named Inventor	Daniel E. AFAR
Examiner Name	G. B. Nickol
Art Unit	1642
Attorney Docket No.	511582001621

## METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit  
Account  
Number

03-1952

Deposit  
Account  
Name

Morrison & Foerster LLP

The Director is authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Credit any overpayments

☒ Charge any additional fee(s) or any underpayment of fee(s)

☐ Charge fee(s) indicated below, except for the filing fee  
to the above-identified deposit account.

## FEE CALCULATION

### 1. BASIC FILING FEE

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1001	770	2001	385	Utility filing fee	
1002	340	2002	170	Design filing fee	
1003	530	2003	265	Plant filing fee	
1004	770	2004	385	Reissue filing fee	
1005	160	2005	80	Provisional filing fee	

SUBTOTAL (1) (\$) 0.00

### 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims		Extra Claims		Fee from below		Fee Paid
17	-20** =		x		=	0.00
2	-3** =		x		=	0.00
Multiple Dependent						

Large Entity		Small Entity		Fee Description
Fee Code	Fee (\$)	Fee Code	Fee (\$)	
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$) 0.00

\*\*or number previously paid, if greater; For Reissues, see above

## FEE CALCULATION (continued)

### 3. ADDITIONAL FEES

Large Entity		Small Entity		Fee Description	Fee Paid
Fee Code	Fee (\$)	Fee Code	Fee (\$)		
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for ex parte reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	420	2252	210	Extension for reply within second month	
1253	950	2253	475	Extension for reply within third month	
1254	1,480	2254	740	Extension for reply within fourth month	
1255	2,010	2255	1,005	Extension for reply within fifth month	
1401	330	2401	165	Notice of Appeal	
1402	330	2402	165	Filing a brief in support of an appeal	
1403	290	2403	145	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,330	2453	665	Petition to revive - unintentional	
1501	1,330	2501	665	Utility issue fee (or reissue)	
1502	480	2502	240	Design issue fee	
1503	640	2503	320	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	180.00
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	770	2809	385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	770	2810	385	For each additional invention to be examined (37CFR 1.129(b))	
1801	770	2801	385	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify)

\*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 180.00

## SUBMITTED BY

(Complete if applicable))

Name (Print/Type)	Kate H. Murashige	Registration No. (Attorney/Agent)	29,959	Telephone	(858) 720-5112
Signature	<i>Kate H. Murashige</i>	Date	June 15, 2004		



PATENT  
Docket No. 511582001621

**CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on June 15, 2004.

*Rhea Amid*  
Rhea Amid

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In the application of:

Daniel E. AFAR et al.

Serial No.: 10/010,667

Filing Date: December 6, 2001

For: PEPTIDES DERIVED FROM STEAP1  
(AS AMENDED)

Examiner: G. B. Nickol

Group Art Unit: 1642

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 09/323,873, filed June 1, 1999, and Serial Number 10/011,095, filed December 6, 2001, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. § 1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

06/22/2004 SSESHE1 00000094 031952 10010667

01 FC:1806 180.00 DA

sd-203504

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☐ Before the mailing of a first Office Action after the filing of a Request for Continued Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☐ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required. However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
- ☒ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
  - ☐ A fee is required. A check in the amount of \_\_\_ is enclosed.
  - ☒ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the amount of \_\_\_ is enclosed.
  - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.)

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing **511582001621**. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: June 16, 2004

Respectfully submitted,

By: Kate H. Murashige  
Kate H. Murashige  
Registration No. 29,959

Morrison & Foerster LLP  
3811 Valley Centre Drive  
Suite 500  
San Diego, California 92130-2332  
Telephone: (858) 720-5112  
Facsimile: (858) 720-5125

Form PTO-1449

Docket Number 511582001621

Application Number 10/010,667

INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Daniel E. AFAR et al.

Filing Date December 6, 2001

Group Art Unit 1642

Mailing Date June 15, 2004

## U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	12/2001	6,329,503	Afar et al.	530	350	

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	2.	04/1998	EP 0 834 563	Europe			
	3.	04/1994	WO 94/09150	WIPO			
	4.	05/1998	WO 98/18489	WIPO			
	5.	08/1998	WO 98/37093	WIPO			
	6.	08/1998	WO 98/37418	WIPO			
	7.	02/1999	WO 99/61469	WIPO			
	8.	12/1999	WO 99/62941	WIPO			
	9.	01/2000	WO 00/04149	WIPO			
	10.	02/2000	WO 00/35937	WIPO			
	11.	02/2001	WO 01/12662	WIPO			

## OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	15.	Haverstick et al., Cancer Research (2000) pp. 1002-1008
	16.	Diss et al., FEBS Letters (1998) 427:5-10
	17.	Grimes and Djamgoz, Journal of Cellular Physiology (1998) 175:50-58
	18.	Skryma et al., The Prostate (1997) 33:112-122
	19.	Gutierrez et al., Journal of Physiology (1999) 517.1:95-107
	20.	Lepple-Wienhues et al., J. Membrane Biol. (1996) 151:149-157
	21.	Marino et al., Tumor Biol. (1994) 15:82-89

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 511582001621

Application Number 10/010,667

Applicant

Daniel E. AFAR et al.

Filing Date December 6, 2001

Group Art Unit 1642

Mailing Date June 15, 2004

**INFORMATION DISCLOSURE CITATION  
IN AN APPLICATION**


(Use several sheets if necessary)

- |     |   |
|-----|---|
| 22. | Pancrazio et al., Cancer Research (1989) 49:5901-5906   |
| 23. | Nie et al., Cell Calcium (1997) 22(2):75-82   |
| 24. | Database EMBL Nucleotide and Protein Sequences, August 25, 1996, XP002128081, AA032221, Hinxton, GB                                     |
| 25. | Database EMBL Nucleotide and Protein Sequences, May 1, 1999, XP002128083, O95034 (clone RG041D11), Hinxton, GB                          |
| 26. | Database EMBL Nucleotide and Protein Sequences, June 15, 1998, XP002128084, AC004969 (clone DJ1121E10), Hinxton, GB                     |
| 27. | Database EMBL Nucleotide and Protein Sequences, May 13, 1997, XP002128082, AC002064, Hinxton, GB  |
| 28. | Abu-Threideh et al., EMBL/GENBANK/DBJ DATABASES, June 1998  |
| 29. | Abu-Threidah et al., GENBANK, (Accession No. 095034), National Library of Medicine, Bethesda MD, May 1, 1999                            |
| 30. | Herbert et al., The Dictionary of Immunology, Academic Press, 4th edition, 1995   |
| 31. | Greenspan et al., Nature Biotechnology (1999) 7:936-937   |
| 32. | Duclert et al., GENBANK, (Accession No. Y11840), National Library of Medicine, Bethesda MD, February 11, 1999                           |
| 33. | Cate et al., GENBANK, (Accession No. W86309), National Library of Medicine, Bethesda MD, November 1998                                  |
| 34. | Gura, Science (1997) 278:1041-1042  |
| 35. | Spitler, Cancer Biotherapy (1995) 10:1-3  |
| 36. | Lal et al., US Patent No. 6,048,970, May 1998, USPTO database sequence listing  |
| 37. | Bellone et al., Immunology Today (1999) 20(10):457-462  |
| 38. | Alberts et al., Molecular Biology of the Cell, 3rd edition, 1994, p.465   |
| 39. | Shantz and Pegg, Int. J. of Biochem. and Cell Biol. (1999) 31:107-122   |
| 40. | McClean and Hill, Eur. J. of Cancer (1993) 29:2243-2248   |
| 41. | Fu et al., EMBO Journal (1996) 15:4392-4401   |
| 42. | Database EMBL "Human BAC clone CTB-167B5 from 7q21, complete sequence," June 17, 1998, XP002173859 (Accession AC 003991 Waterstone, R.) |
| 43. | Hubert et al., PNAS USA (1999) 96(25):14523-14528   |
| 44. | Burgess et al., Jnl. Cell Bio. (1990) 111:2129-2138   |
| 45. | Lazar et al., Mol. Cell Bio. (1988) 8(3):1247-1252  |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number 511582001621	Application Number 10/010,667
<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b> <i>(Use several sheets if necessary)</i> 		Applicant Daniel E. AFAR et al.	
		Filing Date December 6, 2001	Group Art Unit 1642
		Mailing Date June 15, 2004	
	46.	Bowie et al., Science (1990) 247:1306-1310	
	47.	Rieger et al., Glossary of Genetics and Cytogenetics, Springer-Verlag 1976, p. 17	
	48.	International Search Report mailed on May 11, 2004, for PCT patent application no. PCT/US03/18661 filed on June 11, 2003, 3 pages.	
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			
PTO/SB/ 08 (2-92) sd- 203502		Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	